GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fusion Antibodies PLC (LSE:FAB) » Definitions » Price-to-Free-Cash-Flow

Fusion Antibodies (LSE:FAB) Price-to-Free-Cash-Flow : N/A (As of May. 01, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Fusion Antibodies Price-to-Free-Cash-Flow?

As of today (2024-05-01), Fusion Antibodies's share price is £0.03225. Fusion Antibodies's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2023 was £-0.06. Hence, Fusion Antibodies's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Fusion Antibodies's Price-to-Free-Cash-Flow or its related term are showing as below:

LSE:FAB's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 31.685
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Fusion Antibodies's Free Cash Flow per Share for the six months ended in Sep. 2023 was £-0.03. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was £-0.06.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -81.70% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -7.60% per year.

During the past 9 years, Fusion Antibodies's highest 3-Year average Free Cash Flow per Share Growth Rate was 41.00% per year. The lowest was -81.70% per year. And the median was -36.70% per year.


Fusion Antibodies Price-to-Free-Cash-Flow Historical Data

The historical data trend for Fusion Antibodies's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fusion Antibodies Price-to-Free-Cash-Flow Chart

Fusion Antibodies Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only - - - - -

Fusion Antibodies Semi-Annual Data
Mar15 Mar16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Fusion Antibodies's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Fusion Antibodies's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fusion Antibodies's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fusion Antibodies's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Fusion Antibodies's Price-to-Free-Cash-Flow falls into.



Fusion Antibodies Price-to-Free-Cash-Flow Calculation

Fusion Antibodies's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=0.03225/-0.058
=N/A

Fusion Antibodies's Share Price of today is £0.03225.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Fusion Antibodies's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2023 was £-0.06.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Fusion Antibodies  (LSE:FAB) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Fusion Antibodies Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Fusion Antibodies's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Fusion Antibodies (LSE:FAB) Business Description

Traded in Other Exchanges
N/A
Address
1 Springbank Road, Springbank Industrial Estate, Dunmurry, Belfast, GBR, BT17 0QL
Fusion Antibodies PLC offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. It is engaged in the research, development, and manufacturing of recombinant proteins, particularly in the areas of cancer and infectious diseases. Its services include antibody sequencing, antibody humanization, stable cell line development, monoclonal antibody production, and transient protein expression. Geographically company generates the majority of its revenue from North America.

Fusion Antibodies (LSE:FAB) Headlines

From GuruFocus

626 Financial, LLC Buys 3, Sells 2 in 3rd Quarter

By GuruFocus Research GuruFocus Editor 10-21-2022